跳轉至內容
Merck
  • Pharmacologic characterization of human male urethral smooth muscle: an in vitro approach.

Pharmacologic characterization of human male urethral smooth muscle: an in vitro approach.

Urology (2013-12-04)
George T Kedia, Matthias Oelke, Michael Sohn, Markus A Kuczyk, Stefan Ückert
摘要

To elucidate the functional responses of isolated human urethral smooth muscle to various agents known to exert smooth muscle contraction or relaxation. Specimens of penile urethra were obtained from male patients who had undergone male-to-female gender reassignment surgery. Using the tissue bath technique, the contraction induced by increasing concentrations (1 nM-10 μM) of norepinephrine, phenylephrine, acetylcholine, carbachol, prostaglandin F2α, endothelin 1, angiotensin II, and oxytocin was measured. In another set-up, the effects of C-type natriuretic peptide (0.1 nM-1 μM), sodium nitroprusside, sildenafil, forskolin, alpha2-antagonist delquamine, and acetylcholine (1 nM/10 nM-10 μM) on the tension induced by norepinephrine were investigated. The production of cyclic guanosine monophosphate (GMP) and cyclic adenosine monophosphate (AMP) was measured by means of specific radioimmunoassays. Endothelin 1, oxytocin, prostaglandin F2α, norepinephrine, and phenylephrine induced dose-dependent contraction of the isolated urethral tissue, whereas acetylcholine, carbachol, and angiotensin II had no or only minor contractile effects. The contraction induced by norepinephrine was reversed by the drugs with the following rank order of efficacy: sodium nitroprusside > delquamine > sildenafil > C-type natriuretic peptide > forskolin > acetylcholine. The maximal reversion of tension ranged from 68% (sodium nitroprusside) to 22% (acetylcholine). The relaxing effects of the drugs were paralleled by a several-fold increase in tissue levels of cyclic GMP and cyclic adenosine monophosphate. The results provide evidence that urethral smooth muscle is under the control of endogenous compounds, such as adrenergic agonists (norepinephrine and phenylephrine), vasoactive peptides, prostagladins, NO/cyclic GMP, and acetylcholine, assumed to influence micturition at the peripheral level.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
(−)-去甲肾上腺素, ≥98%, crystalline
Sigma-Aldrich
(±)-去甲肾上腺素 (+)-酒石酸氢盐
Sigma-Aldrich
(R)-(−)-去氧肾上腺素 盐酸盐, powder
Sigma-Aldrich
腺苷 3',5'-环单磷酸 钠盐 一水合物, ≥98.0% (HPLC), powder
Sigma-Aldrich
腺苷-3′,5′-环单磷酸, ≥98.5% (HPLC), powder
Sigma-Aldrich
催产素, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin)
Sigma-Aldrich
DL-去甲肾上腺素 盐酸盐, crystalline, ≥97% (TLC)
Sigma-Aldrich
催产素
Sigma-Aldrich
Oxytocin acetate salt hydrate, ≥97% (HPLC)
Sigma-Aldrich
鸟苷 3',5'-环单磷酸, ≥98% (HPLC), powder
Sigma-Aldrich
去甲肾上腺素 盐酸盐, ≥98.0% (sum of enantiomers, HPLC)
Supelco
去氧肾上腺素, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
R-(-)-Phenylephrine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
去氧肾上腺素, European Pharmacopoeia (EP) Reference Standard
去氧肾上腺素, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(R)-(−)-去氧肾上腺素 盐酸盐, analytical standard
催产素, European Pharmacopoeia (EP) Reference Standard